Best diagnostic approach for the genetic evaluation of fetuses after intrauterine death in first, second or third trimester: QF-PCR, karyotyping and/or genome wide SNP array analysis by Kooper, A.J.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://repository.ubn.ru.nl/handle/2066/127688
 
 
 
Please be advised that this information was generated on 2017-03-09 and may be subject to
change.
RESEARCH Open Access
Best diagnostic approach for the genetic
evaluation of fetuses after intrauterine death in
first, second or third trimester: QF-PCR, karyotyping
and/or genome wide SNP array analysis
Angelique JA Kooper*, Brigitte HW Faas, Ilse Feenstra, Nicole de Leeuw and Dominique FCM Smeets
Abstract
Background: The aim of this study was to evaluate the best diagnostic approach for the genetic analysis of
samples from first, second and third trimester intrauterine fetal deaths (IUFDs). We examined a total of 417 IUFD
samples from fetuses with and without congenital anomalies. On 414 samples, karyotyping (N = 46) and/or rapid
aneuploidy testing by QF-PCR (N = 371) was performed). One hundred sixty eight samples with a normal test result
were subsequently tested by genome wide Single Nucleotide Polymorphism (SNP) array analysis. Three samples
were only analyzed by array.
Results: In 50 (12.0%) samples an aneuploidy was detected by QF-PCR and/or karyotyping, representing 47.1% of
first, 13.2% of second and 3.4% of third trimester pregnancies. Karyotyping and QF-PCR failed in 4 (8.7%) and 7 (1.9%)
samples, respectively, concerning mostly contaminated amniotic fluid samples from third trimester pregnancies.
Clinically relevant aberrations were identified in 4.2% (all fetuses with malformations) of the 168 samples tested by SNP
array. Inherited copy number variants (CNVs) were detected in 5.4% and 8.9% showed CNVs of unknown clinical
relevance as parental inheritance could not be studied yet. In a sample from a fetus suspect for Meckel-Grüber
syndrome, the genotype information from the SNP array revealed various stretches of homozygosity, including one
stretch encompassing the CEP290 gene. Subsequent CEP290 mutation analysis revealed a homozygous, pathogenic
mutation in this gene.
Conclusions: Based on our experience we recommend QF-PCR as the first-line test in IUFD samples of first and second
trimester pregnancies to exclude aneuploidy before performing array analysis. The chance to detect aneuploidy in third
trimester pregnancies is relatively low and therefore array analysis can be performed as a first-tier test. A tissue sample,
instead of amniotic fluid, is preferred because of a higher success rate in testing.
We emphasize the need for analysis of parental samples whenever a rare, unique CNV is detected to allow for better
interpretation of such findings and to improve future pregnancy management. Furthermore, we illustrate the strength
of SNP arrays for genotype analysis, even though we realize it is crucial to have detailed phenotypic information to
make optimal use of the genotype data in finding candidate recessive genes that may be related to the fetal
phenotype.
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Background
There are numerous causes of fetal death, including gen-
etic conditions, infections, placental abnormalities, and
fetal-maternal hemorrhage. Valuable tests for the evalu-
ation of fetal death are perinatal autopsy, placental exam-
ination, cytogenetic analysis, and testing for fetal maternal
hemorrhage [1,2]. The first trimester of pregnancy, usually
defined as the period from fertilization until the 13th week
of gestation, is the most sensitive time of development for
the conceptus and a relatively high incidence of first tri-
mester spontaneous abortion is reported. Although mater-
nal exposure to certain teratogens and possible immune
rejection of the conceptus do occur, the most common
cause of first trimester spontaneous abortion is a chromo-
somal abnormality [3-8]. Chromosomal abnormalities
found in second trimester losses are similar to those found
in live births; the most common are trisomies 13, 18, and
21, monosomy X, and sex chromosome polysomies [9].
Second (13–27 weeks) and third trimester (28–42 weeks)
fetal death can also be attributed to many other single or
multiple causes. Beside fetal anomalies placentation and
cord morbidities, or maternal co-morbidities may play a
major role. However, a cause-and-effect relationship is
often difficult to establish. The most common cause of
intrauterine fetal death (IUFD) in the third trimester ap-
pears to be umbilical cord accidents [4-6].
Karyotyping of IUFD samples requires viable cells. As
karyotyping fails in up to 40% of the cases due to culturing
failure, molecular testing of IUFD samples by Multiplex
Ligation-dependent Probe Amplification (MLPA) or
Quantitative Fluorescent Polymerase Chain Reaction (QF-
PCR), for the detection of the most common aneuploidies,
has proven to be very helpful as cell culture is not re-
quired [10,11]. The microarray technology already proved
its value in post- and prenatal diagnostics as it enables the
detection of submicroscopic aberrations (gains and losses)
with a very high resolution [12-20]. Moreover, it over-
comes many of the limitations of routine karyotyping
[7,10,21,22]. Since January 2010 our diagnostic centre rou-
tinely performs array analysis in IUFD samples associated
with congenital anomalies after exclusion of the most
common aneuploidies. Since February 2012 array analysis
is also been performed for IUFD samples without con-
genital anomalies (and without a common aneuploidy).
In this retrospective study, we evaluated the results of
various genetic tests in samples of IUFD from first, sec-
ond and third trimester pregnancies. Next to the results
of traditional karyotyping and QF-PCR, we illustrate the
strength of Single Nucleotide Polymorphisms (SNP)
array analysis based on genotyping data.
Methods
From January 2010 until August 2012, 417 samples of
fetal death in utero were investigated. Genetic studies
were performed on all IUFD samples either by analysis
of material obtained after invasive prenatal testing be-
fore induction of labor (amniotic fluid or chorionic villi,
N = 57) or by analysis of postpartum obtained tissue of
the fetus (fetal skin, placental and/or umbilical cord
material, N = 360). All samples were analyzed at the
Radboud university medical center in Nijmegen for
genetic examination. Gestational age of the pregnancy
and clinical information about the fetus were collected
from the genetic test request form.
DNA for QF-PCR
Tissue samples were minced and treated with collage-
nase to obtain a cell suspension. Subsequently, DNA
was isolated following standard procedures by robot
(Chemagic Magnetic Separation Module 1 from Chemagen,
Baesweiler, Germany).
From chorionic villi, the cytotrophoblast and mesen-
chymal core fraction were enzymatically dissociated
with trypsin/EDTA followed by collagenase treatment.
Genomic DNA for QF-PCR was extracted from both villi
fractions. DNA was extracted from 1 ml uncultured amni-
otic fluid using a Chelex based procedure (Instagene
Matrix, Bio-Rad Laboratories, Hercules, CA, USA).
DNA for array
DNA isolated from tissue samples for QF-PCR was also
used for array.
From chorionic villi, only DNA isolation from the
mesenchymal core fraction was performed for array ana-
lysis using the QIAamp DNA Mini Kit (Qiagen Benelux
BV, Venlo, the Netherlands), following the instructions
of the manufacturer.
From uncultured amniotic fluid, DNA from 6 ml was
isolated, using the QIAamp MinElute Virus spin kit
(Qiagen Benelux BV, Venlo, the Netherlands) and eluted
in 50 μl of elution buffer.
QF-PCR
Two different QF-PCR kits were used: tissue samples were
tested for aneuploidies of the chromosomes 13, 15, 16, 18,
21, 22, X, or Y (kit Devyser Extend, Cytogen, Sinn,
Germany), while chorionic villi and amniotic fluid samples
were tested for aneuploidies of the chromosomes 13, 18,
21, X and Y (Aneufast, Genomed Ltd, UK).
Whenever an aneuploidy was detected, cytogenetic
evaluation of parental blood followed to study whether
the fetal abnormality could be due to a parental
rearrangement.
Karyotyping
In 46 of the 57 chorionic villi or amniotic fluid samples,
karyotyping was the first-line test due to the fact that at
that time the QF-PCR was not yet implemented as a
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first-line test for prenatal IUFD samples. Karyotyping
was performed following standard procedures.
In three samples, culturing of the fetal material and/or
QF-PCR could not be carried out and, therefore, only
array analysis was performed.
Array
After a normal QF-PCR or karyotype result, genome
wide array analysis was performed on DNA from 168
IUFD samples from fetuses with or without malforma-
tions (before February 2012 array was only performed
on IUFD samples with malformations or on request,
from February 2012 routinely on all IUFD samples).
Seventy one samples were tested using the Affymetrix
GeneChip 250 k (NspI) SNP array platform (Affymetrix,
Inc, Santa Clara, California, USA), which contains 25-
mer oligonucleotides representing a total of 262,264
SNPs (Method, see [13]). Data were analyzed with the
CNAG software package [14]. The other 97 array ana-
lyses were carried out following the manufacturer’s pro-
tocols on the high resolution CytoScan HD array
platform which contains more than 2.6 million markers,
including 750,000 genotype-able SNPs and 1.9 million
non-polymorphic probes. Data were analyzed with the
Affymetrix Chromosome Analysis Suite (ChAS) software
(Affymetrix, Inc, Santa Clara, California, USA). The two
major quality control metrics for Affymetrix array are
the Median Absolute Pairwise Difference (MAPD) score
which applies to copy number probes and the SNP-QC
which applies to SNP probes. In our diagnostic setting,
the values for these parameters need to be ≤ 0.25 for
MAPD and ≥ 0.15 for SNP-QC.
We set the cut-offs for our detection criteria for copy
number variants (CNVs) at 20 kb for gains, 10 kb for
losses and 1,250 kb for Regions Of Homozygosity
(ROH). Our reporting criteria for CNVs depend on the
gene content and on the size. Follow-up testing on par-
ental samples is, based on the size of the CNV, per-
formed by array, Fluorescence In Situ Hybridization
(FISH) and/or karyotyping. An overview of our recom-
mendations concerning the detection and reporting cri-
teria for diagnostic array results and follow-up testing
is shown in Table 1. The breakpoint positions of each
aberrant region were converted to UCSC hg19 (UCSC
Genome Browser, release February 2009).
CNVs were classified as (a) benign, (b) likely/probably
benign, (c) of uncertain clinical relevance, (d) of un-
known clinical significance because of unknown inherit-
ance, (e) likely/possibly clinically relevant or (f ) clinically
relevant.
A variant was categorized as benign if its full length
had been reported in at least three apparently unaffected
individuals as listed in the Database of Genomic Variants
[23] or our in-house databases containing array data
from healthy control individuals (i.e., volunteers, blood
donors, etc.). A CNV was likely/probably benign when
an identical CNV was inherited from an healthy parent
and likely/probably clinically relevant whenever the
CNV had been described in a single case report but with
well-defined phenotype, specific and relevant to the
IUFD. Clinically relevant variants had evidence of patho-
genicity according to the published literature, often
containing a gene known to be relevant in fetal develop-
ment or fetal death as listed in the Online Mendelian In-
heritance in Man (OMIM) database. Variants that did
not meet the criteria for classification as clinically rele-
vant or benign were classified as CNVs of uncertain clin-
ical significance, or as CNVs of unknown clinical
significance because of unknown inheritance because
parental inheritance could not be determined yet.
In addition to copy number analysis, SNP array data
analysis also enabled genotyping of the array data and
the detection of homozygous stretches. Regions Of
Homozygosity (ROH) with a size > 10 Mb were evalu-
ated for autosomal recessive conditions in fetuses with a
clinical phenotype using a clinical evaluation tool for
SNP arrays (Genomic Oligoarray and SNP array evalu-
ation tool v2.0) [24]. This tool systematically searches
through relevant databases including the OMIM data-
base, the University of California at Santa Cruz Genome
Browser (UCSC), and the National Center for Biotech-
nology Information (NCBI) database, to rapidly identify
disease genes mapping to the ROH to enumerate associ-
ated autosomal recessive clinical disorders and their
clinical features.
Results
An overview of all samples and diagnostic test results is
shown in Figure 1.
QF-PCR/Karyotyping
In 50 (12.0%) samples an aneuploidy was detected. This
was 47.1% (8/17) in first trimester samples, 13.2% (35/265)
in second trimester samples, 3.4% (4/116) in third tri-
mester samples, and 15.8% (3/19) in the samples of un-
known gestational age. The aneuploidies included trisomy
13 (N = 9), trisomy 18 (N = 4), trisomy 21 (N = 18), mono-
somy X (N= 12), triploidy (N = 6) and one mosaic trisomy
7 (Figure 2).
Karyotyping (N = 46) failed in four (8.7%) amniotic
fluid samples. These four samples were from third tri-
mester pregnancies and were contaminated with old
blood.
QF-PCR (N = 368) failed in seven samples (1.9%). Two
of these were amniotic fluid samples which were con-
taminated with old blood. In both cases, diagnostic test-
ing could successfully be performed by array. In the first
case, also umbilical cord was received and examined,
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Table 1 Recommendations concerning the detection and reporting criteria for diagnostic array results and follow-up testing
Detection criteria Gain Loss ROH
Minimum marker count 10 10 500 (SNP probes)
Minimum size (kb) 20 10 1250
Reporting criteria Gene content of CNV Size of CNV (kb)
Known disease gene, matching the phenotype <20
Known disease gene(s)* >20
No disease gene(s) >100
No genes >500
ROH Size of ROH (Mb)
> 10 Genomic Oligoarray and SNP array evaluation
tool v2.0 [24]→ recessive disease causing genes
→mutation detection
Positive → Parental mutation carrier
analysis
< 10 In case of a specific clinical suspicion for a known
syndrome→ Genomic Oligoarray and SNP array evaluation
tool v2.0 [24]→recessive disease causing genes→mutation
detection
Positive→ Parental mutation carrier
analysis
Parental testing Type of CNV Follow-up test
Uncertain Array analysis
Clinically relevant:
- cytogenetically visible (> 5–10 Mb) Karyotyping
- submicroscopic aberration (<1-10 Mb) FISH
*Depending on the referral reason for array, in this case intrauterine fetal death, a certain CNV will sometimes not be reported, even though our general reporting criteria are met. For example, if it concerns a 50 kb
loss in an OMIM disease gene that is not involved in embryonic and fetal development. Alternatively, a certain CNV is reported, but in the explanatory text of the array report it is mentioned that this CNV is not very
likely causative for the IUFD.
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and in the second case amniotic fluid cells could be cul-
tured and used for DNA isolation and array. The QF-
PCR test of two skin biopsies failed because DNA was of
poor quality due to degradation. We did not obtain in-
terpretable results by QF-PCR in three placenta samples
because of maternal cell contamination. In one sample
with maternal contamination array was performed, the
sample was from a male fetus with an paternally inher-
ited unbalanced translocation t(17;18).
Array
In 168 samples examined by array one test failure
(Cytoscan HD) occurred because the DNA was of poor
quality due to degradation. Six samples did not meet our
quality criteria and were therefore analyzed with an ad-
justed resolution of 1 Mb.
Copy number variants (CNVs)
A normal array profile was detected in 136 out of 168
(81.0%) samples. In seven (4.2%) samples, one or more
(likely) clinically relevant CNVs were detected (Table 1),
with sizes ranging from 1.1 to 48.0 Mb. To define
whether the CNVs had occurred de novo, were inherited,
or caused by the presence of a parental balanced trans-
location, additional parental testing was performed in six
of the seven samples. Only in case id 60 blood was re-
quested but not yet received. Parental karyotyping was
performed in five samples and normal karyotypes were
obtained in nine parents. In case id 206, the father ap-
peared to be carrier of a balanced reciprocal transloca-
tion 46,XY,t(17;18)(q23;q21.1), as is also indicated in the
fetal karyotype in Table 2. Parental testing was per-
formed by FISH in case id 296 and revealed a normal
22q11.2 FISH pattern in both parents.
1
3
3
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11
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1
1
1
2
1
2
0 2 4 6 8 10 12 14 16 18 20
Trisomy 13
Trisomy 18
Trisomy 21
Monosomy 
X
Triploidy 
Other
1st trimester 2nd trimester 3rd trimester unknown gestational age
Figure 1 Distribution, number and type of aneuploidy detected in the cohort of 417 IUFD samples.
Figure 2 Overview of diagnostic testing in 417 IUFD samples. Aneuploidy testing (by QF-PCR or karyotyping) is categorized as normal,
aneuploidy, not performed or failed. Microarray results are indicated as normal (benign CNV), clinically relevant, unknown (CNV of unknown inheritance),
inherited (likely/probably benign CNV) or failed. Mono X: monosomy X; *sample tested by QF-PCR and karyotyping; **two samples tested by both QF-PCR
and karyotyping.
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Table 2 CNVs that are clinically relevant (N = 7)
Case id Pregnancy
trimester
Clinical features Array platform Size
(Mb)
Chromosomal region Start-end Mb
position (Hg19)
CNV Disease-causing OMIM genes
involved (UCSC feb 2009)
60 first Hydrops fetalis CytoScan® HD 8.4 3p24.2p24.3 17269256-25630783 loss THRB
206 unknown MCA 250 k 8.4 17q23.1q25.3 70175362-78598059 gain ~ 19 genes*
26.8 18q21.2q23 49229300-76115293 loss ~ 13 genes*
t(17;18)pat
212 third Unilateral talipes calcaneovalgus,
unilateral ear tag
250 k 11.8 5p15.2p15.33 81949-11834131 dn loss SDHA, SCL6A19, TERT, SLC6A3, NDUFS6,
NSUN2, MTRR, CCT5
4.3 5p15.1p15.2 11857228-16124168 dn gain DNAH5, ANKH
274 second Edema (hands and feet) CytoScan® HD 48.0 1q32.1q44 201214014-249224685 dn gain ~50 genes*
1.1 9p24.3 203862-1293115 dn loss DOCK8, KANK1
37.5 9p13.1p24.3 1293354-38787480 dn gain ~30 genes*
296 second Hypertelorism, micrognathia,
microencephaly, flat face
CytoScan® HD 3.2 22q11.21 18644791-21800798 dn loss PRODH, GP1BB, TBX1, COMT, RTN4R, SCARF2,
HCF2, SNAP29
309 first Exencephaly CytoScan® HD 18.4 18p11.32p11.1 136227-18521286 dn loss SMCHD1, LPIN2, TGIF, NDUFV2, APCDD1, GNAL,
AFG3L2, MC2R
19.3 18q21.32q23 58738938-78014124 dn gain PIGN, TNFRSF11A, BLC2, RTNN, CYB5A, TSHZ1, CTDP1
317 first Hydrops fetalis CytoScan® HD 23.0 9q22.33q33.2 101052575-124018186 dn loss ~20 genes*
*Number of disease-causing OMIM genes > 10→ genes not specified.
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Table 3 CNVs of unknown clinical relevance (due to unknown parental inheritance)
Case id Pregnancy
trimester
Clinical features Array
platform
Size
(kb)
Chrom region Start-end Mb
position (Hg19)
C CNV Ref Seq (and/or disease-causing OMIM)
genes involved (UCSC feb 2009)
2 second Suspect twin to twin transfusion
syndrome (TTTS), clenched fist both
hands, monozygotic twin
250 k 663 4q34.1 173762947-174426181 loss GALNTL6, GALNT7, HMGB2, SAP30, SCRG1
7 second IUGR 250 k 447 3q21.2 125498921-125945498 gain MIR548I1, FAM86JP, ALG1L, ROPN1B, SLC411A3,
ALDH1L1, ALDH1L1-AS1 and AS2
12 second MCA 250 k 587 2p12 77036873-77624262 loss LRRTM4
14 second Unknown, recurrent IUFD 250 k 1,200 6q16.1 95641761-96851236 gain MANEA, FUT9, MANEA-AS1
16 second Hygroma colli 250 k 1,400 1q21.1 143570846-144929606 loss >10 RefSeq genes*, mutation analysis for
Noonan genes: NRAS, SHOC2, GBL, RAF1, SOS1,
KRAS, PTPN11 negative
21 third Hydrocephaly CytoScan® HD 383 16p13.3 3945203-4328143 loss ADCY9, SRL, LOC100507501,TFAP4 (proximal to
OMIM gene CREBBP)
30 second Potter’s sequence, renal agenesis, facial
dysmorfisms, single palmar crease
250 k 1,005 1p32.3 53484565-54489583 gain >10 RefSeq genes* and 3 disease-causing OMIM
genes: SCP2, CPT2, LRP8
34 unknown unknown CytoScan® HD 830 3p24.1 26641410-27471832 gain LRRC3B, NEK10, SLC4A7
39 second None CytoScan® HD 828 Xq28 148839499-149667835 gain MAGEA9B, MAGEA9, MAGEA8-AS1, MAGEA8, CXorf40B,
LINC00894, MIR2114 and 1 disease-causing OMIM gene:
MAMLD1
47 second None CytoScan® HD 358 18q21.2 52900743-53258705 gain MIR4529 and disease-causing OMIM gene TCF4. Duplication
TCF4 confirmed by MLPA.
50 third None CytoScan® HD 545 8p21.3p22 18825888-19370744 loss FSD3, LOC100128993, SH2D4A, CSGALNACT1
20 third None CytoScan® HD 490 3q29 196592132-197081797 gain SENP5, NCBP2, NCBP2-AS2, PIG2, MFI2, MFI2-AS1, DLG1,
DLG1-AS1, MIR4797
55 second None CytoScan® HD 611 16p11.2 29567296-30177917 loss >10 RefSeq genes* and 3 disease-causing OMIM genes:
KIF22, PRRT2, ALDOA
56 second Unknown CytoScan® HD 767 22q11.21 21033398-21800798 loss >10 RefSeq genes* and 2 disease-causing OMIM genes:
HCF2, SNPA29
59 third None CytoScan® HD 266 8p23.3 158049-423802 loss RPL23AP53, ZNT596, FAM87A, FBX025
*Number of Ref Seq genes > 10→ genes not specified.
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In fifteen (8.9%) samples CNVs (12/15 with sizes <1 Mb,
3/15 with sizes between 1–1.4 Mb) were detected of un-
known inheritance (see Table 3). Although parental sam-
ples were requested for carrier testing, these have not
been received so far.
In nine (5.4%) samples a parentally inherited CNV was
detected (Table 4): these were all gains ranging with
sizes < 1 Mb in 8/9 cases and 1.2 Mb in 1/9 cases (6 out
of 8 being maternally inherited).
An overview of all array results is shown in Figure 3.
Regions of Homozygozity (ROH)
In 25 samples, one or more autosomal ROHs were de-
tected with a size ≥ 5 Mb. From 11 of these samples fetal
clinical features were known. By using the online SNP
array evaluation tool [24], all genes with recessive inher-
itance were enumerated to map with the clinical features.
In one of these samples (case id. 336), a homozygous muta-
tion in a recessive disease gene was detected. Case id. 336
is a cord biopsy sample from a fetus, from consanguineous
parents, that died at 14 weeks of gestation. Postpartum
clinical features mentioned on the request form were
meningo-encephalocele, a single umbilical artery and
suspect for Meckel-Grüber syndrome. Meckel-Grüber syn-
drome is an autosomal recessive, early embryonic multi-
systemic disorder (MKS: OMIM 249000). So far, nine
different loci have been mapped, including the CEP290
gene. DNA isolated from a cord biopsy showed a normal
male profile with QF-PCR and array. However, 12.5%
homozygosity of the autosomal genome was detected, in-
cluding a pericentromeric segment of ~80 Mb on chromo-
some 12 encompassing >50 genes, among which the
CEP290 gene (Figure 4). Subsequent mutation analysis of
this gene led to the identification of a pathogenic homozy-
gous missense mutation c.3418G > T. Both parents ap-
peared to be heterozygous carrier of this mutation.
Discussion and conclusions
In the present study, we evaluated different genetic tests
(QF-PCR, karyotyping and array analysis) in the examin-
ation of IUFD samples. Our results show that a common
aneuploidy was detected in 12% of the samples which is
comparable to a previous report of Korteweg et al. [2]
who showed 13% chromosomal abnormalities in a het-
erogeneous cohort of fetal deaths. The percentage of an-
euploidies was highest (47%) in first trimester
pregnancies. This is in line with the reported incidence
of 30-60% of chromosomal anomalies causing early fetal
demise [24-28]. Although cost aspects were not evalu-
ated in our study, aneuploidy detection is cheaper by
QF-PCR than by array and therefore QF-PCR analysis is
the preferred first tier technique before array analysis to
exclude the most common aneuploidies, in particular in
case of a first and second trimester IUFD.
The highest incidence of test failures occurred in am-
niotic fluid samples because of sample contamination. In
2011, we therefore changed our strategy and asked gyne-
cologists to send a fetal biopsy in cases of IUFD instead
of amniotic fluid. The quantity of DNA obtained from
fetal tissue is usually sufficient, it is clean and therefore
suitable for testing by both QF-PCR and array analysis
and additional sequencing of single genes in case of a
suspected monogenic disorder.
In our cohort with a normal QF-PCR result, a clinic-
ally relevant CNV was detected by array in 4.2% of the
samples, varying in size from 1.1 to 48.0 Mb and all con-
cerning fetuses with malformations. This is lower than
reported in literature. However, in these papers, the
genome-wide prevalence of CNVs was examined in truly
unexplained stillbirth, resulting in an overall detection
ranging from 8-13% [11,29]. Retrospective studies in fe-
tuses with multiple malformations also obtained a detec-
tion rate of causative imbalances from 8 to 15%, including
Table 4 Inherited CNVs (N = 9)
Case id Pregnancy
trimester
Clinical features Array platform Size
(kb)
Chromosomal
region
Inheritance Start-end Mb
position (Hg19)
CNV
242 second Recurrent miscarriages,
micrognatia
250 k 559 22q12.3 maternal 31829608-32388222 gain
257 second Unknown 250 k 400 1p31.1 maternal 71586877-71986553 gain
272 second Hydrops fetalis, low-set ears,
Pierre Robin Sequence (PRS)
CytoScan® HD 303 Xq24 maternal 118733984-119037053 gain
280 second Unknown CytoScan® HD 251 6q27 paternal 169570833-169822659 gain
281 second Mild facial dysmorfic features,
hypertelorism, long philtrum
CytoScan® HD 1,200 1q43 maternal 236830156-238009186 gain
289 second Agenesis of the corpus callosum
(ACC), hydrops fetalis, ascites,
mild ventriculomegaly
CytoScan® HD 260 9q21.11 maternal 71570080-71842392 gain
316 second Unknown CytoScan® HD 367 16p13.3 maternal 5393095-5760407 gain
359 second None (recurrent miscarriages) CytoScan® HD 990 7q11.21 paternal 65329349-66417018 gain
65 second Unknown (macerated fetus) CytoScan® HD 294 Xp22.31 paternal 8439472-8733564 gain
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common aneuploidies, by using array [7,30-32]. Our co-
hort tested by array, however, consisted of a heteroge-
neous group of fetal deaths, excluding a common
aneuploidy which could clarify our lower detection rate.
Overall, in 8.9% of the samples a CNV was detected
with unknown inheritance, most of which (12/15)
smaller than 1 Mb in size. In contrast to our routine
prenatal diagnostic array workflow, in which it is highly
recommended to include parental samples simultan-
eously, in IUFD genetic analysis, testing of parental sam-
ples is requested in our written report only after a likely
pathogenic CNV has been detected. To reduce the
[------------------- -------------------------]
A
B
37857750-94282972 bp
Figure 4 A region of homozygosity in chromosome 12, including the CEP290 gene.
7
15
9
1
136
Clinically relevant CNV
CNV of unknown clinical significance because of unknown inheritance
Likely/probably benign CNV (inherited CNV) 
Test failure
Normal array result
Figure 3 Overview of array results: type and number of CNVs detected in 168 samples with IUFD.
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number of results with CNVs of unknown inheritance
and therefore unknown clinical relevance, the maximum
effort possible should be undertaken to obtain parental
blood for testing. Subsequently, finding the cause of the
IUFD is helpful to better understand the cause of death,
to more accurately determine the recurrence risks, and
to enable possible future testing in some cases.
In eight (4.8%) samples a CNV inherited from a
healthy parent was detected. Although not all inherited
CNVs can always be classified as benign and without
clinical relevance with certainty, they are, dependent
on the size and the type of CNV, less likely to directly
lead to a clinical phenotype: small CNVs (< 0.1 Mb)
and gains are less likely to be pathogenic than large
CNVs (>1 Mb) and losses, respectively [33,34]. All
inherited CNVs in this study were gains ranging in size
from ~250 - 1,200 kb, mostly maternally inherited and
most likely benign.
The utility of high density SNP arrays is not only use-
ful to rule out potential sample mismatch or false-
paternity, but is also used in our laboratory for the
examination of regions of homozygosity (ROH) [16,35]
and to identify excessive homozygosity, and with specific
clinical information the possibility for follow-up diagnos-
tic testing. A nice example in our cohort for demonstrat-
ing the power of homozygosity mapping was case id.
336, suspect for Meckel-Grüber syndrome. A homozy-
gous mutation was found in CEP290, one of the genes
within a large, 80 Mb ROH. Both parents appeared to be
heterozygous carriers of this mutation. The Genomic
Oligoarray and SNP array evaluation tool enables to
evaluate homozygous stretches for autosomal recessive
genes in combination with a clinical phenotype making
it possible to strategize more focused diagnostic testing
[24]. Therefore, we emphasize the need to have detailed
phenotypic information to make optimal use of the
genotype data from SNP arrays in finding candidate re-
cessive disease genes that may be related to the fetal
phenotype.
In concordance with the results of a study of 532 still-
birth samples [36], we conclude that array analysis is
more likely to provide an accurate genetic diagnosis than
by traditional karyotyping, primarily because of its suc-
cess with nonviable tissue, making array particularly
valuable in the analysis of stillbirths with congenital
anomalies. An increased detection rate of chromosomal
abnormalities is found when array analysis is used to
examine products of conception [37], however, further
work is required before the absolute detection rate can
be answered.
Nowadays, next-generation sequencing (NGS) is in-
creasingly being used in genetic diagnostics for studying
congenital malformations, intellectual disability, and
other heterogeneous disorders. Although mutations in
genes are known to cause fetal death [38], a systematic
genome-wide study has not been performed yet, leaving
a large proportion of fetal demise unexplained. It is
already demonstrated that NGS not only enables the de-
tection of Single Nucleotide Variation but CNVs as well
[39], thus very soon replacing genome wide array ana-
lysis in diagnostics. Implementation of NGS for CNV
detection and genome/exome wide sequencing in the
work-up of IUFD will not only lead to a further im-
provement of the detection rate, but also to a better fun-
damental insight in fetal and placental development, and
possible maternal interactions.
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